Summit Partners Public Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Summit Partners Public Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-42,000	Closed	-$5.09M	–	190
2023 Q3	$5.09M	Sell	42,000 -285,700	-87%	-$32.3M	0.22%	96
2023 Q2	$37.5M	Buy	327,700 +174,700	+114%	+$22.5M	1.39%	23
2023 Q1	$21.1M	Buy	+153,000	New	+$19.8M	0.87%	46
2018 Q4	–	Sell	-69,900	Closed	-$11.3M	–	89
2018 Q3	$11.3M	Buy	+69,900	New	+$9.56M	0.76%	47

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Summit Partners Public Asset Management's SRPT Position: Q1 2025 in Review

Summit Partners Public Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 379,150 shares — an estimated $46.1M sold.

Summit Partners Public Asset Management first reported a position in SRPT in Q4 2017 and held it in 12 quarters. The position peaked at $46.1M in Q4 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Summit Partners Public Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Summit Partners Public Asset Management sold 379,150 Sarepta Therapeutics shares in Q1 2025, an estimated $46.1M.
Summit Partners Public Asset Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 12 quarters.
Summit Partners Public Asset Management's Sarepta Therapeutics position peaked at $46.1M in Q4 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2025, filed 15 May 2025.